A third COVID-19 vaccine has proven effective in late-stage testing.
AstraZeneca, headquartered in the United Kingdom, announced Monday that its vaccine has shown to be 90% effective. Trials were conducted in the U.K. and in Brazil with about 23,000 subjects.
The vaccine will also be cheaper and easier to distribute that those from Pfizer and Moderna. AstraZeneca says its vaccine does not have to be stored in ultra-cold conditions, a big benefit in rural areas and developing countries around the globe.
The company has also committed to not making a profit on the vaccine, bringing its per-dose price to about $2.50. Pfizer’s vaccine will cost about $20 and Moderna’s between $15 and $25.
Additional trials are underway around the globe including in the U.S.
Pending approval, AstraZeneca expects to be able to begin distribution in January 2021.